| Trial | Treatments | Patients | Method |
|---|
| Dejager [1], 2007 | vildagliptin 50 mg or 100 mg daily (n=-9) vs. placebo (n=-9) | drug-naïve patients with type 2 diabetes | double-blind Sample size: -9/-9 Primary endpoint: FU duration: 24 weeks |
| Mimori, 2006 | vildagliptin 20 mg or 50 mg or 100 mg daily (n=-9) vs. placebo (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: |
| Pi-Sunyer, 2007 | vildagliptin 50 mg or 100 mg daily, imag (n=-9) vs. placebo (n=-9) | drug-naïve patients with type 2 diabetes | double-blind Sample size: -9/-9 Primary endpoint: FU duration: 24 weeks |
| Pratley, 2006 | vildagliptin 25mg bid (n=70) vs. placebo (n=28) | | double-blind Sample size: 70/28 Primary endpoint: FU duration: |
| Ristic, 2005 | vildagliptin 25mg or 50mg or 100mg daily (n=-9) vs. placebo (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: |
| Scherbaum [2], 2008 | vildagliptin 50 mg qd (n=156) vs. placebo (n=150) | drug-naïve patients with type 2 diabetes and mild hyperglycaemia | double-blind Parallel groups Sample size: 156/150 Primary endpoint: FU duration: 52 weeks |
| Rosenstock* (vilda vs rosi), 2007 | vildagliptin 100 mg daily daily (n=519) vs. rosiglitazone 8 mg once daily (n=267) | drug-naïve patients with type 2 diabetes | double-blind Sample size: 519/267 Primary endpoint: FU duration: 24 weeks |
| Rosenstock** (vilda vs pio), 2007 | vildagliptin 100 mg daily daily (n=-9) vs. pioglitazone 30 mg dailyaily (n=-9) | drug-naive patients with type 2 diabetes | double-blind Sample size: -9/-9 Primary endpoint: FU duration: |
| Schweizer, 2007 | vildagliptin 100mg (n=526) vs. metformin up to 2000 mg daily (n=254) | drug-naïve patients with Type 2 diabetes | Sample size: 526/254 Primary endpoint: FU duration: 52 weeks |
| Ahren, 2004 | vildagliptin 50 mg daily (add-on to metformin therapy)j (n=56) vs. placebo (add-on to metformin therapy)mag (n=51) | patients with type 2 diabetes | double-blind Sample size: 56/51 Primary endpoint: FU duration: 12 weeks |
| Bolli, 2008 | vildagliptin 100 mg daily (add-on to metformin therapy) (n=295) vs. pioglitazone 30 mg daily (add-on to metformin therapy)j (n=281) | patients with type 2 diabetes inadequately controlled with metformin monotherapy | double-blind Sample size: 295/281 Primary endpoint: FU duration: |
| Bosi, 2007 | vildagliptin (50 or) 100 mg daily (add-on to metformin therapy)m (n=185) vs. placebo (add-on to metformin therapy)mag (n=182) | patients with type 2 diabetes inadequately controlled with metformin | double-blind Sample size: 185/182 Primary endpoint: FU duration: |
| Fonseca, 2007 | vildagliptin 100 mg daily (add-on to insulin therapy)y) (n=144) vs. placebo (add-on to insulin therapy)y)mag (n=152) | type 2 diabetes that was inadequately controlled by insulin | double-blind Sample size: 144/152 Primary endpoint: FU duration: 24 weeks |
| Garber, 2007 | vildagliptin 50 or 100 mg daily (add-on to pioglitazone therapy) (n=463) vs. placebo (add-on to pioglitazone therapy) (n=0) | | Sample size: 463/0 Primary endpoint: FU duration: |
| Rosenstock** (vilda + pio vs pio), 2007 | vildagliptin 50 mg or 100 mg daily plus 15 mg or 30 mg pioglitazone dailyi (n=-9) vs. pioglitazone 30 mg daily (n=-9) | drug-naive patients with type 2 diabetes | double-blind Sample size: -9/-9 Primary endpoint: FU duration: 24 weeks |
| Ferrannini, 2009 | vildagliptin 50 mg twice daily (n=1396) vs. glimepiride titrated up to 6 mg/day (n=1393) | Patients inadequately controlled on metformin monotherapy (HbA(1c) 6.5-8.5%) | double-blind Parallel groups Sample size: 1396/1393 Primary endpoint: HbA1c FU duration: 52 weeks |
| Goodman, 2009 | ildagliptin 100 mg given in the morning, vildagliptin 100 mg given in the evening (n=125) vs. placebo (n=122) | patients inadequately controlled with metformin | double-blind Parallel groups Sample size: 125/122 Primary endpoint: FU duration: 24 weeks |
| Filozof, 2009 | vildagliptin (50 mg twice daily (n=513) vs. gliclazide (up to 320 mg/day (n=494)
| patients with Type 2 diabetes inadequately controlled with metformin
| double-blind Sample size: 513/494 Primary endpoint: FU duration: 52 weeks
|
| Goke, 2008 | vildagliptin (100 mg daily) (n=-9) vs. metformin (2 000 mg daily). (n=-9) | drug-naïve patients with type 2 diabetes | Sample size: -9/-9 Primary endpoint: FU duration: |
| Foley, 2009 | monotherapy with vildagliptin 50 mg bid (n=-9) vs. gliclazide up to 320 mg/day (n=-9) | drug-naïve patients with type 2 diabetes | double-blind Sample size: -9/-9 Primary endpoint: FU duration: 2 years |
| Pan, 2008 | vildagliptin (100 mg daily, given as 50 mg twice daily (n=441) vs. acarbose (up to 300 mg daily, given as three equally divided doses (n=220) | drug-naive patients with Type 2 diabetes | double-blind Sample size: 441/220 Primary endpoint: FU duration: 24 weeks |
| Rosenstock, 2008 | vildagliptin (50 mg q.d.) (n=-9) vs. placebo (n=-9) | subjects with impaired glucose tolerance | double-blind Sample size: -9/-9 Primary endpoint: FU duration: 12 weeks |
| Schweizer, 2009 | vildagliptin (100 mg daily (n=169) vs. metformin (titrated to 1500 mg daily (n=166) | drug-naïve patients with type 2 diabetes aged>or=65 years | Sample size: 169/166 Primary endpoint: FU duration: |
| Bosi, 2009 | vildagliptin plus high-dose metformin combination therapy (50 mg + 1000 mg twice daily), (n=1179) vs. high-dose metformin monotherapy (1000 mg twice daily). (n=0) | treatment-naive patients with type 2 diabetes mellitus | Sample size: 1179/0 Primary endpoint: FU duration: 24 weeks |
| Garber, 2008 | vildagliptin (50 mg given once or twice daily) (n=515) vs. placebo (n=0) | patients with type 2 diabetes inadequately controlled with a sulphonylurea | double-blind Sample size: 515/0 Primary endpoint: FU duration: 24 weeks |
| NCT00101673 | vildagliptin (n=-9) vs. (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: |
| Foley, 2011 | vildagliptin 100 mg (n=29) vs. placebo (n=30) | drug-naive patients with type 2 diabetes and mild hyperglycaemia | Sample size: 29/30 Primary endpoint: FU duration: |
| GALIANT (Blonde), 2009 | vildagliptin 100 mg (n=1653) vs. TZD (agent and dose at the investigators' discretion (n=825) | patients inadequately controlled [haemoglobin A(1C) (HbA(1c)): 7-10%] on a stable dose of metformin (> or =1000 mg/day). | Sample size: 1653/825 Primary endpoint: FU duration: |
| Kikuchi, 2009 | vildagliptin 50mg bid (n=-9) vs. placebo (n=-9) | Japanese patients with type 2 diabetes mellitus | Sample size: -9/-9 Primary endpoint: FU duration: |
| CLAF237A 23104 | (n=-9) vs. (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: |
| NCT00728351 | Vildagliptin and Metformin (25/1000 mg Bid) (n=-9) vs. Metformin Monotherapy (1000 mg Bid) (n=-9) | Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy | Sample size: -9/-9 Primary endpoint: FU duration: |
| Kikuchi, 2010 | vildagliptin 50mg twice-daily (n=102) vs. placebo (n=100) | Japanese patients with Type 2 diabetes mellitus | double-blind Sample size: 102/100 Primary endpoint: FU duration: 12 weeks |
| NCT00822211 | Vildagliptin 50 mg Bid or qd (n=-9) vs. placebo (n=-9) | Chinese Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy | Parallel groups Sample size: -9/-9 Primary endpoint: FU duration: 24 weeks |
| NCT00368134 | Vildagliptin 50 mg Bid (n=-9) vs. Voglibose 0.2 mg Tid (n=-9) | patients with type 2 diabetes | Sample size: -9/-9 Primary endpoint: FU duration: 12 weeks |
| NCT00351832 | vildagliptin 50mg qd, 50mg bid or 100mg qd (n=-9) vs. placebo (n=-9) | Patients With Type 2 Diabetes | Parallel groups Sample size: -9/-9 Primary endpoint: FU duration: 12 weeks |
| NCT00494884 (Wollmer) | Vildagliptin 100 mg o.d. (n=-9) vs. placebo (n=-9) | Patients With Type 2 Diabetes Inadequately Controlled With Metformin | Sample size: -9/-9 Primary endpoint: FU duration: |
| Ahren, 2009 | vildagliptin (100 mg/d) (n=-9) vs. placebo (n=-9) | drug-naive patients with type 2 diabetes | Cross over Sample size: -9/-9 Primary endpoint: FU duration: |
| NCT00396071 | vildagliptin (n=-9) vs. placebo (n=-9) | Patients With Type 2 Diabetes Treated With Metformin | Cross over Sample size: -9/-9 Primary endpoint: FU duration: |
| Rosenstock, 2009 | vildagliptin (50 mg b.i.d (n=396) vs. rosiglitazone (8 mg q.d., (n=202) | drug-naïve type 2 diabetes mellitus patients | double-blind Sample size: 396/202 Primary endpoint: FU duration: |
| Lukashevich , 2011 | vildagliptin (50 mg qd) (n=-9) vs. placebo (n=-9) | patients with type 2 diabetes mellitus (T2DM) and moderate or severe renal impairment | Sample size: -9/-9 Primary endpoint: FU duration: 24 weeks |
| Matthews , 2010 | vildagliptin (n=-9) vs. glimepiride (n=-9) | patients with type 2 diabetes mellitus inadequately controlled (HbA1c 6.5-8.5%) by metformin monotherapy | double-blind Parallel groups Sample size: -9/-9 Primary endpoint: FU duration: 2 years |
| Iwamoto, 2010 | vildagliptin (50 mg bid, (n=188) vs. voglibose (0.2 mg tid (n=192) | Japanese patients with T2D who were inadequately controlled with diet and exercise | double-blind Sample size: 188/192 Primary endpoint: FU duration: 12 weeks |
| Fonseca , 2008 | vildagliptin added to insulin (n=-9) vs. (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: |
